,,ii  #aahth ,,congress  #ast ,session  
,s4 #bcfd  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,july #ah1     
#bjbc,mr4 ,peters 7for himself1 ,mr4    
,lankford1 and ,mr4 ,braun7 introduced  
the following bill2 which was read twice
 and referred to the ,committee on      
,health1 ,education1 ,labor1 and        
,pensions  ,a ,,bill  ,to map the       
,united ,states pharmaceutical supply   
chain and use data analytics to identify
 supply chain vulnerabilities and other 
national security threats4  #a4 ,short  
title ,this ,act may be cited as the    
,mapping ,america's ,pharmaceutical     
,supply ,act or the ,,maps ,act4  #b4   
,federal ,u4,s4 pharmaceutical supply   
chain mapping  7a7 ,in general ,the     
,secretary of ,health and ,human        
,services1 in coordination with the     
heads of other relevant agencies1       
including the ,secretary of ,defense and
 the ,secretary of ,homeland ,security1 
shall support efforts1 including through
 public-private partnerships1 to map the

 entire ,united ,states pharmaceutical  
supply chain1 from inception to         
distribution1 and use data analytics to 
identify supply chain vulnerabilities   
and other national security threats4    
,such activities shall include1 at      
minimum-- 7#a7 defining agency roles in 
monitoring the pharmaceutical supply    
chain and communicating supply chain    
vulnerabilities2  7#b7 establishing a   
database of drugs selected from the     
essential medicines list developed by   
the ,food and ,drug ,administration in  
response to ,executive ,order #acidd    
7#he ,fed4 ,reg4 #diibi7 and any other  
relevant assessments or lists1 as       
appropriate1 to identify1 in            
coordination with the private sector1 a 
list of essential medicines1 to be      
updated regularly and published on a    
timeframe that the ,secretary of ,health
 and ,human ,services1 in coordination  
with the ,secretary of ,defense and the 
,secretary of ,homeland ,security1      
determines appropriate1 which shall     

include the drugs and the active        
pharmaceutical ingredients of such drugs
 that-- 7,a7 are reasonably likely to be
 required to respond to a public health 
emergency or to a chemical1 biological1 
radiological1 or nuclear threat2 or     
7,b7 the shortage of which would pose a 
significant threat to the ,united       
,states health care system or at-risk   
populations2 and  7#c7 with respect to  
drugs selected for inclusion in the     
database pursuant to paragraph 7#b71    
identifying-- 7,a7 the location of      
establishments registered under         
subsection 7b71 7c71 or 7i7 of section  
#eaj of the ,federal ,food1 ,drug1 and  
,cosmetic ,act 7#ba ,u4,s4,c4 #cfj7     
involved in the production of active    
pharmaceutical ingredients and finished 
dosage forms1 and the amount of such    
ingredients and finished dosage forms   
produced at each such establishment2    
7,b7 to the extent available1 the       
location of establishments so registered
 involved in the production of the key  

starting materials and excipients needed
 to produce the active pharmaceutical   
ingredients and finished dosage forms1  
and the amount of such materials and    
excipients produced at each such        
establishment2 and  7,c7 any regulatory 
actions with respect to the             
establishments manufacturing such drugs1
 including with respect to labeling     
requirements1 registration and listing  
information required to be submitted    
under section #eaj of the ,federal      
,food1 ,drug1 and ,cosmetic ,act 7#ba   
,u4,s4,c4 #cfj71 inspections and related
 regulatory activities conducted under  
section #gjd of such ,act 7#ba ,u4,s4,c4
 #cgd71 the seizure of such a drug      
pursuant to section #cjd of such ,act   
7#ba ,u4,s4,c4 #ccd71 any recalls of    
such a drug2 inclusion of such a drug on
 the drug shortage list under section   
#ejf;,e of such ,act 7#ba ,u4,s4,c4     
#cef;e71 or prior drug shortages reports
 of a discontinuance or interruption in 
the production of such a drug under     

#ejf;,c of such ,act 7#ba ,u4,s4,c4     
#cee;d74  7b7 ,report ,not later than   
#ah months after the date of enactment  
of this ,act1 and annually thereafter1  
the ,secretary of ,health and ,human    
,services1 in consultation with the     
heads of agencies with which such       
,secretary coordinates under subsection 
7a71 shall submit a report to ,congress 
on-- 7#a7 progress on implementing      
subsection 7a71 including any timelines 
for full implementation1 if any2  7#b7  
gaps in data needed for full            
implementation of such subsection2  7#c7
 how the database established under     
subsection 7a77#b7 increases ,federal   
visibility into the pharmaceutical      
supply chain2  7#d7 how ,federal        
agencies are able to use data analytics 
to conduct predictive modeling of       
anticipated drug shortages or national  
security threats2 and  7#e7 the extent  
to which industry has cooperated in     
mapping the pharmaceutical supply chain 
and building the database described in  

subsection 7a77#b74  7c7 ,confidential  
commercial information ,the exchange of 
information among the ,secretary of     
,health and ,human ,services and the    
heads of other relevant agencies1       
including the ,secretary of ,defense and
 the ,secretary of ,homeland ,security1 
for purposes of carrying out this       
section shall not be a violation of     
section #aije of title #ah1 ,united     
,states ,code4  7d7 ,clarification ,the 
database established under this section 
shall not be publicly disclosed4        
,nothing this subsection shall be       
construed to relieve the ,secretary of  
,health and ,human ,services from its   
obligation to provide information to    
,congress4